{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:33:08Z","timestamp":1792521188563,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2019CDF-2662 Pfkelch13 emergence"],"award-info":[{"award-number":["TMA2019CDF-2662 Pfkelch13 emergence"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Substandard anti-malarial agents pose a significant challenge to effective malaria control and elimination efforts especially in sub-Saharan Africa. The quality of anti-malarials in most low-and-middle income countries (LMICs) is affected by several factors including inadequate regulation and limited resources. In this study, the pharmacopeial quality of artemether\u2013lumefantrine (AL) in low and high malaria transmission settings in Uganda was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a cross-sectional study conducted among randomly selected private drug outlets. The AL anti-malarials available in drug outlets were purchased using overt method. The samples were screened for quality using visual inspection, weight uniformity, content assay and dissolution tests. The assay test was done using liquid chromatography\u2013mass spectrometry (LC\u2013MS). The samples were considered substandard if the active pharmaceutical ingredient (API) content was outside 90\u2013110% range of the label claim. Dissolution test was conducted following United States Pharmacopoeia (USP) method. Data was analysed using descriptive statistics and presented as means with standard deviations, frequencies, and proportions. Correlation between medicine quality and independent variables was determined using Fisher\u2019s exact test of independence at 95% level of significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 74 AL anti-malarial samples were purchased from high (49\/74; 66.2%) and low (25\/74; 33.8%) malaria transmission settings. The most common batch of AL was LONART, 32.4% (24\/74), with 33.8% (25\/74) being \u2018Green leaf\u2019. Overall prevalence of substandard quality artemether\u2013lumefantrine was 18.9% (14\/74; 95% CI: 11.4\u201329.7). Substandard quality AL was significantly associated with setting (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). A total of 10 samples (13.5%) failed artemether content assay test while, 4 samples (5.4%, 4\/74) failed the lumefantrine assay test. One sample from a high malaria transmission setting failed both artemether and lumefantrine assay content test. Of the samples that failed artemether assay test, 90% had low (&lt;\u200990%) artemether content. All the samples passed visual inspection and dissolution tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Artemether\u2013lumefantrine agents, the recommended first-line treatment for uncomplicated malaria with APIs outside the recommended pharmacopeial content assay limit is common especially in high malaria transmission settings. There is need for continuous surveillance and monitoring of the quality of artemisinin-based anti-malarials across the country by the drug regulatory agency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-023-04600-8","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T03:01:50Z","timestamp":1685070110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacopeial quality of artemether\u2013lumefantrine anti-malarial agents in Uganda"],"prefix":"10.1186","volume":"22","author":[{"given":"Moses","family":"Ocan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loyce","family":"Nakalembe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Otike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Omali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Buzibye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Nsobya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"4600_CR1","volume-title":"World Malaria report 2021","author":"WHO","year":"2021","unstructured":"WHO. World Malaria report 2021. Geneva: World Health Organization; 2021."},{"key":"4600_CR2","doi-asserted-by":"publisher","first-page":"e0264339","DOI":"10.1371\/journal.pone.0264339","volume":"17","author":"K Marwa","year":"2022","unstructured":"Marwa K, Kapesa A, Baraka V, Konje E, Kidenya B, Mukonzo J, et al. Therapeutic efficacy of artemether\u2013lumefantrine, artesunate-amodiaquine and dihydroartemisininpiperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2022;17:e0264339.","journal-title":"PLoS ONE"},{"key":"4600_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1473-3099(12)70064-6","volume":"12","author":"GML Nayyar","year":"2012","unstructured":"Nayyar GML, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis. 2012;12:488\u201396.","journal-title":"Lancet Infect Dis"},{"key":"4600_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.trstmh.2006.01.003","volume":"100","author":"CT Lon","year":"2006","unstructured":"Lon CT, Tsuyuoka R, Phanouvong S, Nivanna N, Socheat D, Sokhan C, et al. Counterfeit and substandard antimalarial medicines in Cambodia. Trans R Soc Trop Med Hyg. 2006;100:1019\u201324.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4600_CR5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S1473-3099(06)70581-3","volume":"6","author":"PN Newton","year":"2006","unstructured":"Newton PN, Green MD, Fern\u00e1ndez FM, Day NP, White NJ. Counterfeit anti-infective drugs. Lancet Infect Dis. 2006;6:602\u201313.","journal-title":"Lancet Infect Dis"},{"key":"4600_CR6","volume-title":"A study on the public health and socioeconomic impact of substandard and falsified medical products","author":"WHO","year":"2017","unstructured":"WHO. A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva: World Health Organization; 2017."},{"key":"4600_CR7","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.4269\/ajtmh.21-1123","volume":"106","author":"S Ozawa","year":"2022","unstructured":"Ozawa S, Chen HH, Lee YA, Higgins CR, Yemeke TT. Characterizing medicine quality by active pharmaceutical ingredient levels: a systematic review and meta-analysis across low- and middle-income countries. Am J Trop Med Hyg. 2022;106:1778\u201390.","journal-title":"Am J Trop Med Hyg"},{"key":"4600_CR8","doi-asserted-by":"publisher","first-page":"e2132","DOI":"10.1371\/journal.pone.0002132","volume":"3","author":"R Bate","year":"2008","unstructured":"Bate R, Oticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa\u2014a six country study. PLoS ONE. 2008;3:e2132.","journal-title":"PLoS ONE"},{"key":"4600_CR9","volume-title":"Survey of the quality of medicines identified by the UN Commission on life-saving commodities","author":"WHO","year":"2016","unstructured":"WHO. Survey of the quality of medicines identified by the UN Commission on life-saving commodities. Geneva: World Health Organization; 2016."},{"key":"4600_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12936-018-2628-3","volume":"18","author":"S Ozawa","year":"2019","unstructured":"Ozawa S, Evans DR, Higgins CR, Laing SK, Awor P. Development of an agent-based model to assess the impact of substandard and falsified antimalarials: Uganda case study. Malar J. 2019;18:5.","journal-title":"Malar J"},{"key":"4600_CR11","doi-asserted-by":"publisher","first-page":"e0217910","DOI":"10.1371\/journal.pone.0217910","volume":"14","author":"SM Beargie","year":"2019","unstructured":"Beargie SM, Higgins CR, Evans DR, Laing SK, Erim D, Ozawa S. The economic impact of substandard and falsified antimalarial medications in Nigeria. PLoS ONE. 2019;14:e0217910.","journal-title":"PLoS ONE"},{"key":"4600_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4269\/ajtmh.14-0725","volume":"92","author":"JP Renschler","year":"2015","unstructured":"Renschler JP, Walters KM, Newton PN, Laxminarayan R. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa. Am J Trop Med Hyg. 2015;92:119\u201326.","journal-title":"Am J Trop Med Hyg"},{"key":"4600_CR13","volume-title":"World Malaria Report 2014","author":"WHO","year":"2014","unstructured":"WHO. World Malaria Report 2014. Geneva: World Health Organization; 2014."},{"key":"4600_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14787210.2016.1187560","volume":"14","author":"PN Newton","year":"2016","unstructured":"Newton PN, Caillet C, Guerin PJ. A link between poor quality antimalarials and malaria drug resistance? Expert Rev Anti Infect Ther. 2016;14:531\u20133.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4600_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1475-2875-8-253","volume":"8","author":"NJ White","year":"2009","unstructured":"White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J. 2009;8:253.","journal-title":"Malar J"},{"key":"4600_CR16","volume-title":"The international pharmacopoeia","author":"WHO","year":"2020","unstructured":"WHO. The international pharmacopoeia. 10th ed. Geneva: World Health Organization; 2020.","edition":"10"},{"key":"4600_CR17","unstructured":"United States Pharmacopeia and National Formulary (USP 44 -NF 39). Rockville: United States Pharmacopeial Convention; 2021."},{"key":"4600_CR18","doi-asserted-by":"publisher","first-page":"894","DOI":"10.4269\/ajtmh.17-0732","volume":"98","author":"B Schiavetti","year":"2018","unstructured":"Schiavetti B, Wynendaele E, De Spiegeleer B, Mbinze GJ, Kalenda N, Marini R, et al. The quality of medicines used in children and supplied by private pharmaceutical wholesalers in Kinshasa, Democratic Republic of Congo: a prospective survey. Am J Trop Med Hyg. 2018;98:894\u2013903.","journal-title":"Am J Trop Med Hyg"},{"key":"4600_CR19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12936-019-2872-1","volume":"18","author":"S Belew","year":"2019","unstructured":"Belew S, Suleman S, Mohammed T, Mekonnen Y, Duguma M, Teshome H, et al. Quality of fixed dose artemether\/lumefantrine products in Jimma Zone. Ethiopia Malar J. 2019;18:236.","journal-title":"Ethiopia Malar J"},{"key":"4600_CR20","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/j.1365-3156.2004.01342.x","volume":"9","author":"AM Dondorp","year":"2004","unstructured":"Dondorp AM, Newton PN, Mayxay M, Van Damme W, Smithuis FM, Yeung S, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health. 2004;9:1241\u20136.","journal-title":"Trop Med Int Health"},{"key":"4600_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1475-2875-13-139","volume":"13","author":"P Tabernero","year":"2014","unstructured":"Tabernero P, Fern\u00e1ndez FM, Green M, Guerin PJ, Newton PN. Mind the gaps\u2013the epidemiology of poor-quality anti-malarials in the malarious world\u2013analysis of the Worldwide Antimalarial Resistance Network database. Malar J. 2014;13:139.","journal-title":"Malar J"},{"key":"4600_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4269\/ajtmh.14-0535","volume":"92","author":"M Hajjou","year":"2015","unstructured":"Hajjou M, Krech L, Lane-Barlow C, Roth L, Pribluda VS, Phanouvong S, et al. Monitoring the quality of medicines: results from Africa, Asia, and South America. Am J Trop Med Hyg. 2015;92:68\u201374.","journal-title":"Am J Trop Med Hyg"},{"key":"4600_CR23","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(00)05085-6","volume":"16","author":"P Newton","year":"2001","unstructured":"Newton P, Proux S, Green M, Smithuis F, Rozendaal J, Prakongpan S, et al. Fake artesunate in southeast Asia. Lancet. 2001;16:1948\u201350.","journal-title":"Lancet"},{"key":"4600_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12936-017-1814-z","volume":"16","author":"S Tougher","year":"2017","unstructured":"ACTwatch Group, Tougher S, Hanson K, Goodman C. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism. Malar J. 2017;16:173.","journal-title":"Malar J"},{"key":"4600_CR25","doi-asserted-by":"publisher","first-page":"e92323","DOI":"10.1371\/journal.pone.0092323","volume":"9","author":"M Ocan","year":"2014","unstructured":"Ocan M, Bwanga F, Bbosa GS, Bagenda D, Waako P, Ogwal-Okeng J, et al. Patterns and predictors of self-medication in Northern Uganda. PLoS ONE. 2014;9:e92323.","journal-title":"PLoS ONE"},{"key":"4600_CR26","doi-asserted-by":"publisher","first-page":"e181662","DOI":"10.1001\/jamanetworkopen.2018.1662","volume":"1","author":"S Ozawa","year":"2018","unstructured":"Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. JAMA Netw Open. 2018;1:e181662.","journal-title":"JAMA Netw Open"},{"key":"4600_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"4600_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","volume":"223","author":"V Asua","year":"2021","unstructured":"Asua V, Conrad MD, Aydemir O, Duvalsaint M, Legac J, Duarte E, et al. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J Infect Dis. 2021;223:985\u201394.","journal-title":"J Infect Dis"},{"key":"4600_CR29","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"4600_CR30","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ng.3189","volume":"47","author":"O Miotto","year":"2015","unstructured":"Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet. 2015;47:226\u201334.","journal-title":"Nat Genet"},{"key":"4600_CR31","doi-asserted-by":"crossref","unstructured":"Osei-Safo D, Agbonon A, Konadu DY, Harrison JJEK, Edoh M, Gordon A, et al. Evaluation of the quality of artemisinin-based antimalarial medicines distributed in Ghana and Togo. Malar Res Treat. 2014:806416.","DOI":"10.1155\/2014\/806416"},{"key":"4600_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.tips.2009.11.005","volume":"31","author":"PN Newton","year":"2010","unstructured":"Newton PN, Green MD, Fernandez FM. Impact of poor-quality medicines in the \u2018developing\u2019 world. Trends Pharmacol Sci. 2010;31:99\u2013101.","journal-title":"Trends Pharmacol Sci"},{"key":"4600_CR33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-3156.2006.01785.x","volume":"12","author":"EA Ashley","year":"2007","unstructured":"Ashley EA, Stepniewska K, Lindeg\u00e5rdh N, McGready R, Annerberg A, Hutagalung R, et al. Pharmacokinetic study of artemether\u2013lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop Med Int Health. 2007;12:201\u20138.","journal-title":"Trop Med Int Health"},{"key":"4600_CR34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","volume":"44","author":"F Ezzet","year":"2000","unstructured":"Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697\u2013704.","journal-title":"Antimicrob Agents Chemother"},{"key":"4600_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1517\/14656566.8.1.75","volume":"8","author":"G Kokwaro","year":"2007","unstructured":"Kokwaro G, Mwai L, Nzila A. Artemether\/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother. 2007;8:75\u201394.","journal-title":"Expert Opin Pharmacother"},{"key":"4600_CR36","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1473-3099(12)70241-4","volume":"12","author":"AO Talisuna","year":"2012","unstructured":"Talisuna AO, Karema C, Ogutu B, Juma E, Logedi J, Nyandigisi A, et al. Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet Infect Dis. 2012;12:888\u201396.","journal-title":"Lancet Infect Dis"},{"key":"4600_CR37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12936-019-2955-z","volume":"18","author":"NJ White","year":"2019","unstructured":"White NJ. Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance. Malar J. 2019;18:338.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04600-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-023-04600-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04600-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T03:03:03Z","timestamp":1685070183000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-023-04600-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4600"],"URL":"https:\/\/doi.org\/10.1186\/s12936-023-04600-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1992901\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by Makerere University School of Biomedical Sciences Research Ethics Committee (SBS 803). The protocol was further reviewed and cleared by Uganda National Council of Science and Technology (UNCST), (HS1169ES). Administrative clearance was also obtained from the local district authorities in the study. In each drug outlet, a written informed consent was obtained from the pharmacist prior to data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}